The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial

Autor: A Molassiotis, W Russell, J Hughes, M Breckons, M Lloyd-Williams, J Richardson, C Hulme, S Brearley, M Campbell, A Garrow, WD Ryder

Publikováno v: Health Technology Assessment, Vol 17, Iss 26 (2013)

Background: Chemotherapy-induced nausea and vomiting remain difficult symptoms to manage in clinical practice. As standard antiemetic drugs do not fully eliminate these symptoms, it is important to explore the adjuvant role of non-pharmacological and

Externí odkaz: https://doaj.org/article/39a43a3bbbd24df8b2d9a7b3a4739d85

Prognostic relevance of micro-vessel density in cancer of the urinary bladder

Autor: Chaudhary R, Bromley M, Noel Clarke, Cd, Betts, Rj, Barnard, Wd, Ryder, Kumar S

Publikováno v: Europe PubMed Central

Angiogenesis is an important factor in tumour growth and metastasis. Degree of angiogenesis (microvascular density-MVD) has been found to correlate with tumour progression and disease outcome in a number of different malignancies. We studied 88 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::dc3d6d4f878338f70533271461eddc6d
https://pubmed.ncbi.nlm.nih.gov/10629639

A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).

Autor: Griffiths-Jones DJ; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK., Garcia YS; Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK., Ryder WD; Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK., Pauling JD; Department of Rheumatology, Royal United Hospitals Bath NHS Trust, Bath, UK., Hall F; Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Lanyon P; Department of Rheumatology, Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK., Bhat S; Department of Rheumatology, Ninewells Hospital and Medical School, Dundee, UK., Douglas K; Department of Rheumatology, Dudley Group NHSFT, Dudley, UK., Gunawardena H; Rheumatology Department, North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bristol, UK., Akil M; Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Anderson M; Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Griffiths B; Department of Rheumatology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Del Galdo F; NIHR Biomedical Research Centre and Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Youssef H; Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, UK., Madhok R; Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK., Arthurs B; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK., Buch M; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.; NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Fligelstone K; Royal Free Hospital, London, UK., Zubair M; Research Governance and Integrity, The University of Manchester, Manchester, UK., Mason JC; National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK., Denton CP; Centre for Rheumatology, UCL Division of Medicine, Royal Free Campus, London, UK., Herrick AL; NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Sep 01; Vol. 62 (9), pp. 3133-3138.

Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.

Autor: Lamarca A; Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester M20 4BX,, UK., Palmer DH; University of Liverpool and Clatterbridge Cancer Centre, Liverpool, UK., Wasan HS; Department of Cancer Medicine, Hammersmith Hospital, Imperial Colllege London, London, UK., Ross PJ; Guy's Cancer, Guy's & St Thomas' NHS Foundation Trust, London, UK., Ma YT; Department of Hepatobiliary Oncology, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Arora A; Department of Medical Oncology, University Hospital of Nottingham NHS Trust, University of Nottingham, Nottingham, UK., Falk S; Bristol Haematology and Oncology Centre, Bristol, UK., Gillmore R; Department of Medical Oncology, Royal Free NHS Foundation Trust, London, UK., Wadsley J; Weston Park Cancer Centre, Sheffield, UK., Patel K; Department of Medical Oncology, Cancer and Haematology Centre, Oxford, UK., Anthoney A; Department of Medical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Maraveyas A; Department of Medical Oncology, Hull University Teaching Hospitals NHS Trust, Hull, UK., Iveson T; Department of Gastro- Intestinal Oncology, University Hospital Southampton NHS Foundation Trust, Southampton University, Southampton, UK., Waters JS; Kent Oncology Centre, Maidstone, UK., Hobbs C; Department of Clinical Oncology, Great Western Hospital, Swindon, UK., Barber S; Manchester Clinical Trials Unit, University of Manchester, Manchester M20 4BX, UK., Ryder WD; Manchester Clinical Trials Unit, University of Manchester, Manchester M20 4BX, UK., Ramage J; Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK., Davies LM; Manchester Centre for Health Economics, University of Manchester, Manchester M20 4BX, UK., Bridgewater JA; UCL Cancer Institute, University College London, London, UK., Valle JW; Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester M20 4BX,, UK; Division of Cancer Sciences, University of Manchester, Manchester M20 4BX, UK. Electronic address: juan.valle@manchester.ac.uk.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2021 Jul; Vol. 22 (7), pp. e288-e289.

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

Autor: Lamarca A; Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester, UK., Palmer DH; University of Liverpool and Clatterbridge Cancer Centre, Liverpool, UK., Wasan HS; Department of Cancer Medicine, Hammersmith Hospital, Imperial Colllege London, London, UK., Ross PJ; Guy's Cancer, Guy's & St Thomas' NHS Foundation Trust, London, UK., Ma YT; Department of Hepatobiliary Oncology, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Arora A; Department of Medical Oncology, University Hospital of Nottingham NHS Trust, University of Nottingham, Nottingham, UK., Falk S; Bristol Haematology and Oncology Centre, Bristol, UK., Gillmore R; Department of Medical Oncology, Royal Free NHS Foundation Trust, London, UK., Wadsley J; Weston Park Cancer Centre, Sheffield, UK., Patel K; Department of Medical Oncology, Cancer and Haematology Centre, Oxford, UK., Anthoney A; Department of Medical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Maraveyas A; Department of Medical Oncology, Hull University Teaching Hospitals NHS Trust, Hull, UK., Iveson T; Department of Gastro-Intestinal Oncology, University Hospital Southampton NHS Foundation Trust, Southampton University, Southampton, UK., Waters JS; Kent Oncology Centre, Maidstone, UK., Hobbs C; Department of Clinical Oncology, Great Western Hospital, Swindon, UK., Barber S; Manchester Clinical Trials Unit, University of Manchester, Manchester, UK., Ryder WD; Manchester Clinical Trials Unit, University of Manchester, Manchester, UK., Ramage J; Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK., Davies LM; Manchester Centre for Health Economics, University of Manchester, Manchester, UK., Bridgewater JA; UCL Cancer Institute, University College London, London, UK., Valle JW; Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: juan.valle@manchester.ac.uk.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2021 May; Vol. 22 (5), pp. 690-701. Date of Electronic Publication: 2021 Mar 30.